AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
SLQT Shareholders May Lead Class Action Lawsuit Amid Allegations of Medicare Advantage Plan Misconduct
ByAinvest
Monday, Aug 18, 2025 5:57 pm ET1min read
Investors who purchased SelectQuote, Inc. (NYSE: SLQT) securities between September 9, 2020 and May 1, 2025 may be entitled to compensation due to alleged false and misleading statements made by the company. To join the class action lawsuit, visit rosenlegal.com/submit-form/?case_id=39510 or call Phillip Kim, Esq. at 866-767-3653. A lead plaintiff must move the Court no later than October 10, 2025.
Investors who purchased SelectQuote, Inc. (NYSE: SLQT) securities between September 9, 2020 and May 1, 2025 may be entitled to compensation due to alleged false and misleading statements made by the company. Two separate class action lawsuits have been filed against SelectQuote, Inc., alleging that the company engaged in fraudulent activities and misrepresented its business practices.Key Details of the Lawsuits
- Filing Law Firms: Bernstein Liebhard LLP and The Law Offices of Frank R. Cruz have filed separate class action lawsuits on behalf of investors.
- Class Period: The lawsuits cover the period from September 9, 2020 to May 1, 2025.
- Allegations: The complaints allege that SelectQuote, Inc. made materially false and misleading statements, failed to disclose material adverse facts, and engaged in illegal kickbacks from health insurance companies to steer Medicare beneficiaries to certain plans. These actions resulted in investors suffering financial losses.
- Lead Plaintiff Deadline: Investors have until October 10, 2025, to move the court to serve as lead plaintiff in the Bernstein Liebhard LLP lawsuit. For the Law Offices of Frank R. Cruz lawsuit, the deadline is 60 days from the date of the notice.
Impact on SelectQuote, Inc.
Following the filing of the lawsuits and the Department of Justice's False Claims Act complaint, SelectQuote, Inc.'s stock price fell significantly. On May 1, 2025, the stock price decreased by $0.61, or 19.2%, to close at $2.56 per share.
Next Steps for Investors
Investors who purchased SelectQuote, Inc. securities during the specified period are encouraged to review the details of the lawsuits and consider their legal rights. To join the class action lawsuit, visit [Rosen Legal](https://rosenlegal.com/submit-form/?case_id=39510) or call Phillip Kim, Esq. toll-free at 866-767-3653.
References:
[1] https://www.globenewswire.com/news-release/2025/08/18/3134969/0/en/SHAREHOLDER-ALERT-Bernstein-Liebhard-LLP-Announces-A-Securities-Fraud-Class-Action-Lawsuit-Has-Been-Filed-Against-SelectQuote-Inc-NYSE-SLQT.html
[2] https://www.morningstar.com/news/business-wire/20250811153040/slqt-class-action-notice-the-law-offices-of-frank-r-cruz-files-securities-fraud-lawsuit-against-selectquote-inc
[3] https://www.prnewswire.com/news-releases/repl-investors-have-opportunity-to-lead-replimune-group-inc-securities-lawsuit-first-filed-by-the-rosen-law-firm-302530462.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet